A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs

Sponsor
Hoffmann-La Roche (Industry)
Overall Status
Completed
CT.gov ID
NCT00002367
Collaborator
(none)
40
2
20

Study Details

Study Description

Brief Summary

To evaluate the efficacy of Saquinavir-SGC combination with Zidovudine and Lamivudine in the treatment of HIV-1 infected patients with no previous anti-retroviral drug therapy.

Condition or Disease Intervention/Treatment Phase
Phase 3

Detailed Description

All enrolled patients will receive the following 3 drug combination: Saquinavir, Zidovudine and Lamivudine. Efficacy and duration of anti-viral response will be evaluated by monitoring of HIV-1 RNA levels. Patients below the detectable limit of 200 copies/ml will be analyzed using the Ultra-direct method with a detection limit of 20 copies/ml. CD4 and CD8 cell counts will also be analyzed.

Study Design

Study Type:
Interventional
Intervention Model:
Parallel Assignment
Primary Purpose:
Treatment
Official Title:
An Open-Label, Non-Comparative Study of Saquinavir-SGC in Combination With Zidovudine (AZT) and Lamivudine (3TC) in the Treatment of HIV-1 Infected Patients With No Previous Anti-Retroviral Drug Therapy

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    16 Years to 0 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria

    Patients must have:
    • Plasma HIV-1 RNA titers > 10,000 copies/ml.

    • CD4 cell count > 100 cells/mm3.

    Exclusion Criteria

    Co-existing Condition:
    Patients with any of the following conditions will be excluded:
    • Any prior anti-retroviral drug therapy.
    Prior Medication:
    Excluded:

    Previous anti-retroviral drug therapy.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 AIDS Healthcare Foundation Labs Los Angeles California United States 90048
    2 Urgent Care Ctr / North Broward Hosp District Fort Lauderdale Florida United States 33316

    Sponsors and Collaborators

    • Hoffmann-La Roche

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00002367
    Other Study ID Numbers:
    • 229F
    • NR15503
    • M61005
    First Posted:
    Aug 31, 2001
    Last Update Posted:
    Jun 24, 2005
    Last Verified:
    Aug 1, 1997

    Study Results

    No Results Posted as of Jun 24, 2005